HC Wainwright Comments on Edesa Biotech Q2 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Edesa Biotech in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst V. Bernardino anticipates that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for Edesa Biotech’s Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

Edesa Biotech (NASDAQ:EDSA) last announced its quarterly earnings data on Friday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.17). During the same period in the prior year, the firm posted ($0.54) EPS.

Edesa Biotech Stock Up 2.1 %

Shares of NASDAQ EDSA opened at $2.44 on Monday. Edesa Biotech has a twelve month low of $1.55 and a twelve month high of $5.59. The firm has a market cap of $17.06 million, a P/E ratio of -1.30 and a beta of 0.77. The company has a 50 day moving average of $2.10 and a 200 day moving average of $2.75.

Hedge Funds Weigh In On Edesa Biotech

A hedge fund recently bought a new stake in Edesa Biotech stock. Two Sigma Securities LLC bought a new position in Edesa Biotech, Inc. (NASDAQ:EDSA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,313 shares of the company’s stock, valued at approximately $26,000. Two Sigma Securities LLC owned 0.44% of Edesa Biotech at the end of the most recent quarter. 5.50% of the stock is owned by institutional investors and hedge funds.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.